Apatinib and camrelizumab plus TACE before liver resection for centrally-located BCLC‑B hepatocellular carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-arm Phase II trial conducted at Tongji Hospital that gives neoadjuvant therapy combining transarterial chemoembolization (TACE) with the oral VEGFR2 inhibitor apatinib and the PD‑1 antibody camrelizumab before planned liver resection. Eligible patients are adults (18–70) with centrally-located, resectable BCLC stage B HCC who have not received prior anti-tumor treatment and have adequate organ and liver function. The study aims to downstage tumors, increase the rate of complete (R0) resections and reduce early recurrence while monitoring safety and tolerability. Outcomes will include tumor response, resection margin status, recurrence and survival measures as well as treatment-related adverse events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\) Diagnosed with hepatocellular carcinoma by pathological or histological examination.
* 2\) the patient do not receive any anti-tumor treatment, including but not limited to surgery, radiotherapy, chemotherapy, immunotherapy and targeted therapy
* 3)resectable centrally-located hepatocellular carcinoma in BCLC stage B; Surgical resection was feasible after MDT discussion.
* 4\) aged 18 to 70 years old, male or female
* 5\) at least one measurable lesions (according to RECISTv1.1 requirements, The long diameter of the measurable lesion in the spiral CT scan is ≥10 mm or The short diameter of the enlarged lymph nodes is ≥15 mm)
* 6\) ECOG score between 0 to 2, Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤5 ULN, total serum bilirubin TBIL ≤1.5 ULN, creatinine (Cr)≤1.5ULN, HB≥80g/L, neutrophil \> 1.5×109/L ,Serum albumin \> 28 g/L
* 7\) Child - Pugh grade A or B (7 points or less); ICG - R15 \< 20%
* 8\) Sufficient future liver reserve (FLR): For patients with liver cirrhosis, FLR should be greater than 40% of the standard liver volume; for patients without liver cirrhosis, FLR should be greater than 30% of the standard liver volume.
* 9\) After assessment, TACE treatment can be deemed suitable.
* 10\) The subjects signed the informed consent form and voluntarily received the neoadjuvant treatment of Apatinib mesylate and Carlimzumab combined with TACE. They had good compliance and cooperated with the follow-up.

Exclusion Criteria:

* 1\) Patients with intrahepatic cholangiocarcinoma (ICC), mixed hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, or fibrolamellar hepatocellular carcinoma.
* 2\) Patients with a history of malignant tumors other than liver cancer.
* 3\) Patients with recurrent HCC after surgery who have received local or systemic treatment (chemotherapy, radiotherapy, surgery, interventional therapy, ablation, alcohol injection, or molecular targeted therapy).
* 4\) Patients who are currently receiving or have previously received organ transplantation or allogeneic bone marrow transplantation, or have immune deficiency diseases or a history of organ transplantation.
* 5\) Patients with vascular or biliary tumor thrombus or extrahepatic organ metastasis as shown by imaging.
* 6\) Patients with moderate to severe ascites requiring therapeutic puncture and drainage or uncontrolled pleural effusion or pericardial effusion.
* 7\) Patients with dysfunction of cardiovascular, respiratory, nervous, digestive, or urinary systems.
* 8\) Patients with a history of gastrointestinal bleeding within 6 months before the start of the study, with a tendency to gastrointestinal bleeding, abdominal fistula, gastrointestinal perforation, or abdominal abscess.
* 9\) Patients with multiple factors affecting oral drug administration (such as inability to swallow, chronic diarrhea, and intestinal obstruction, which significantly affect drug intake and absorption); patients allergic to the active ingredients or excipients of Camrelizumab and Apatinib mesylate.
* 10\) Pregnant or lactating women; patients with reproductive capacity who are unwilling or unable to take effective contraceptive measures.
* 11\) Patients with mental disorders or a history of abuse of psychotropic drugs.
* 12\) Patients who have experienced thrombosis or embolism events within 6 months before the start of the study, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), pulmonary embolism, etc.
* 13\) Patients without legal capacity or with restricted legal capacity.
* 14\) Patients with any other conditions that the investigator deems unsuitable for participation in this trial.

Where it's running

• Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: WeiZhang, MD
• Email: weizhangtjh@hust.edu.cn
• Phone: 086-13986029425

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VRT106 plus camrelizumab and apatinib for advanced HCC in patients who have tried prior ICIs

  This study tests VRT106, with camrelizumab and apatinib, to see if it helps people with advanced hepatocellular carcinoma who have already had prior immune checkpoint inhibitors fail.

  Recruiting Phase 2/3 Guangzhou Virotech Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07589244

• Y-90 microspheres with camrelizumab and/or apatinib versus Y-90 alone or cTACE for unresectable liver cancer

  This trial will test whether adding camrelizumab and/or apatinib to Y-90 microsphere treatment helps people with unresectable, non-metastatic hepatocellular carcinoma more than Y-90 alone or conventional TACE.

  Recruiting at 2 sites Phase 2 GrandPharma (China) Co., Ltd. · Beijing and 2 other locations · NCT07334483

• Camrelizumab plus apatinib with or without FOLFOX chemotherapy for advanced liver cancer

  This research will test whether adding FOLFOX chemotherapy to camrelizumab plus apatinib helps adults with advanced hepatocellular carcinoma who have not received prior systemic treatment.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07267806

• TUDCA with camrelizumab and regorafenib for advanced hepatocellular carcinoma after anti‑PD‑1/PD‑L1 plus bevacizumab

  This trial tests whether adding TUDCA to camrelizumab and regorafenib helps people with advanced hepatocellular carcinoma that got worse after anti‑PD‑1/PD‑L1 plus bevacizumab.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07100392

• Perioperative radiotherapy with SOX chemotherapy plus apatinib and camrelizumab for esophagogastric cancer

  This trial tests whether adding apatinib and camrelizumab to SOX chemotherapy and radiotherapy before and after surgery helps adults with locally advanced gastric or GEJ adenocarcinoma.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07026149

• Camrelizumab plus apatinib and eribulin versus physician's choice chemotherapy for advanced triple-negative breast cancer

  This trial tests whether combining camrelizumab, apatinib, and eribulin works better than your doctor's chosen chemotherapy for adults with advanced triple-negative breast cancer who have had 1–4 prior systemic treatments.

  Recruiting at 5 sites Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong and 6 other locations · NCT06889688

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.